On December 5, 2025, PharmaCyte Biotech, Inc. (PMCB) disclosed receiving a Nasdaq non-compliance notice for failing to meet the minimum $1.00 bid price requirement. The 8-K filing disclosed the company has 180 calendar days, until June 1, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2).

According to the filing, PharmaCyte Biotech received the written notice from The Nasdaq Stock Market LLC Listing Qualifications Department on December 1, 2025. The notice indicates the company is not in compliance with the Bid Price Rule, which requires a minimum closing bid price of $1.00 per share for continued listing on The Nasdaq Capital Market.

The company has an initial 180-day period, ending June 1, 2026, to regain compliance. To achieve compliance, PharmaCyte Biotech's closing bid price must reach at least $1.00 per share for a minimum of 10 consecutive business days during this period, according to the filing. The notice has no immediate effect on the listing or trading of the company's common stock.

If the company does not regain compliance by the June 1, 2026 deadline, it may be eligible for an additional 180-day compliance period if it meets other listing requirements and provides written notice of intent to cure. The filing also notes that PharmaCyte Biotech may implement a reverse stock split, subject to stockholder approval, to address the bid price deficiency.

The 8-K filing was signed by Chief Executive Officer and President Joshua N. Silverman. The company stated there is no assurance it will be able to regain or maintain compliance with the Bid Price Rule or other continued listing requirements.